HEALTHglobal
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific - Fierce Biotech
Single source
Updated 2 hours ago
First seen March 23, 2026 16:34:26Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Sanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecific Fierce Biotech